Orexigen (OREX) Slumps as Many Expected 'Better News' for Contrave

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 7/10/2026

1. SKHY
2. USO
3. SPY
4. META
5. DAL
6. PEP
7. SKHYV
8. ALP
9. NRIX
10. KBH

Go back to Orexigen (OREX) Slumps as Many Expected 'Better News' for Contrave

JPMorgan Confident Orexigen's (OREX) Will Receive FDA Approval; Comments on Meeting

December 21, 2012 11:56 AM EST

Orexigen Therapeutics (Nasdaq: OREX) shares are up on the session following a little pressure earlier in the week on its Contrave NDA resubmission.

JPMorgan is out with comments following Orexigen's analyst day this week. The firm remains confident on approvability of Contrave and that any good news from Arena Pharmaceuticals (Nasdaq: ARNA) and VIVUS, Inc. (Nasdaq:... More

Orexigen (OREX) Updates on Contrave; to Resubmit NDA, Sees FDA Approval in Q413

December 18, 2012 8:32 AM EST

Orexigen Therapeutics, Inc. (Nasdaq: OREX) provided a clinical trial update of the Light Study as well as results of recent market research at its Analyst Day meeting in New York City. Orexigen reported that the screening of new patients for the Light Study, the cardiovascular outcomes trial evaluating Contrave® (Naltrexone SR/Bupropion SR), is now complete. Approximately 9,000 patients will be randomized in the study within the next few weeks. An interim analysis of the Light Study will occur after approximately 87 major adverse cardiovascular events (MACE) are accrued in the study. Although it... More